论文部分内容阅读
卵巢癌是女性癌症死亡的第五大原因。卵巢癌患者高死亡率是由于缺乏早期症状及晚期诊断所导致，并且存在治疗选择的局限性以及抗肿瘤药物的耐药性。目前，分子靶点已成为肿瘤靶向治疗的重要手段，CD (clusters of differentiations) 24是一种小的唾液酸糖蛋白，通过其糖基磷脂酰肌醇(glycosylphosphatidylinositol，GPI)锚定位于脂筏中。尽管CD24的表达与癌细胞的发展、侵袭和转移密切相关，但CD24在癌细胞中的确切作用尚不清楚。目前的研究表明，CD24在卵巢癌以及许多癌症中存在过表达，CD24也被鉴定为卵巢癌干细胞标记物。最近，CD24已被确定为卵巢癌患者存活的具有独立预后意义的特定分子靶点。接下来，我们将回顾卵巢癌靶向治疗中的分子靶点，并概述新的分子靶点CD24及其与卵巢癌的密切关系。“,”Ovarian cancer is the fifth cause of death from cancer in women. The high mortality rate in patients with ovarian cancer is due to the lack of early symptoms and advanced diagnosis, and there are limitations in treatment options and resistance to anti-tumor drugs. At present, molecular targets have become an important means of tumor targeted therapy. CD (clusters of differentiations) 24 is a small sialic acid glycoprotein that is localized in lipid rafts by its glycosylphosphatidylinositol GPI anchor. Although the expression of CD24 is closely related to the development of cancer cells, invasion and metastasis, the exact role of CD24 in cancer cells is unclear. Current research indicates that CD24 is overexpressed in ovarian cancer as well as in many cancers, and CD24 has also been identified as an ovarian cancer stem cell marker. Recently, CD24 has been identified as a specific molecular target with independent prognostic significance for the survival of ovarian cancer patients. Next, we will review the molecular targets in ovarian cancer targeted therapy and outline the new molecular target CD24 and its close relationship with ovarian cancer.